These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22208047)

  • 1. [Bisphosphonate against patients with hormone refractory prostate cancer].
    Shinohara N
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():576-80. PubMed ID: 22208047
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone complications: an increasing risk in patients with prostate cancer.
    J Support Oncol; 2007 Feb; 5(2):88-9. PubMed ID: 17348369
    [No Abstract]   [Full Text] [Related]  

  • 3. [Progress in treatment of metastatic tumors in the bone by bisphosphonate].
    Dong M; Chen XP; Feng FY
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):801-3. PubMed ID: 18396633
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 5. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
    Saad F; Sternberg CN
    Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The if's, and's, or but's regarding bisphosphonates for prostate cancer.
    Wilt TJ; Ensrud KE
    J Natl Cancer Inst; 2007 May; 99(10):744-5. PubMed ID: 17505065
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone continuum of cancer.
    Lipton A
    Am J Clin Oncol; 2010 Jun; 33(3 Suppl):S1-7. PubMed ID: 20526089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biphosphonates and prostatic cancer. A survey of a Cochrane review].
    Jønler M; Borre M
    Ugeskr Laeger; 2007 Nov; 169(47):4058-61. PubMed ID: 18078660
    [No Abstract]   [Full Text] [Related]  

  • 12. Bisphosphonates for care and cure.
    Body JJ
    Eur J Cancer; 2009 Sep; 45 Suppl 1():396-7. PubMed ID: 19775644
    [No Abstract]   [Full Text] [Related]  

  • 13. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?
    Valcamonico F; Petrelli F; Ferrari L; Ferrari V; Grisanti S; Barni S; Berruti A
    J Clin Oncol; 2014 Nov; 32(32):3684-5. PubMed ID: 25225432
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone disease in prostate cancer.
    Nagrial A; Horvath L
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):3-4. PubMed ID: 20398032
    [No Abstract]   [Full Text] [Related]  

  • 19. Skeletal-related events in prostate cancer.
    Smith MR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
    [No Abstract]   [Full Text] [Related]  

  • 20. [The role of bisphosphonate in the treatment of bone metastases from prostate cancer].
    Sallami S; Ben Rhouma S; Cherif K; Benrais N; Horchani A
    Tunis Med; 2012 Jul; 90(7):507-11. PubMed ID: 22811222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.